Our team of medical professionals is evaluating an investigational medication designed to suppress an enzyme called myeloperoxidase (MPO), believed to cause inflammation and damage to neurons in the brains of patients with multiple system atrophy. The main purpose of the study is to see if it helps slow disease progression.
The investigational medication tablets are taken twice daily. Patients who are already taking stable doses of medications used to treat MSA symptoms may be able to continue their current medications while participating in the study.
After determining eligibility, study participation lasts for about 11 months and requires participation from a patient caregiver who will need to attend seven study visits spread out over that time with the patient.